ARTICLE | Distillery Therapeutics


October 20, 2016 7:00 AM UTC

Mouse studies suggest inhibiting ACAC could help treat NSCLC. In a xenograft mouse model and two genetic mouse models of NSCLC, the ACAC inhibitor ND-646 decreased tumor growth and tumor fatty acid synthesis compared with vehicle. In the genetic models, ND-646 plus the generic chemotherapy carboplatin decreased tumor growth compared with either agent alone. Next steps could include IND-enabling studies of ND-646...